IVIVC approach based on carbamazepine bioequivalence studies combination

Area of Science:

• Pharmacokinetics and Drug Formulation
• Pharmaceutical Sciences
• Biopharmaceutics

Background:

• Establishing in vitro-in vivo correlations (IVIVC) is crucial for predicting drug performance.
• Bioequivalence (BE) studies provide essential in vivo data for developing IVIVC.
• Carbamazepine (CBZ) immediate-release (IR) products require robust dissolution testing methods.

Purpose of the Study:

• To assess the feasibility of developing an IVIVC for carbamazepine (CBZ) by combining data from multiple bioequivalence (BE) studies.
• To determine if previously established dissolution media and conditions are applicable to other oral IR CBZ products.
• To validate a universal biopredictive dissolution medium for CBZ.

Main Methods:

• Combined data from two bioequivalence studies involving 24 healthy male subjects receiving IR carbamazepine (CBZ) formulations (test 1 or 2, and reference Tegretol 400 mg).
• Conducted dissolution studies of IR CBZ tablets in two independent laboratories.
• Developed Level C, B, and A correlations using individual and average data analysis, focusing on R2 values for in vivo and in vitro data combinations.

Main Results:

• Successfully developed Level C, B, and A in vitro-in vivo correlations (IVIVC) by integrating data from multiple carbamazepine (CBZ) bioequivalence studies.
• Achieved a robust Level A IVIVC across all four datasets, demonstrating good R2 values for in vivo and in vitro data combinations.
• Identified a dissolution medium containing 1% SLS as a suitable universal biopredictive medium for IR CBZ products, irrespective of batch variations or study combinations.

Conclusions:

• Combining bioequivalence data from multiple studies is feasible for developing robust in vitro-in vivo correlations (IVIVC) for carbamazepine (CBZ).
• A 1% SLS dissolution medium demonstrated effectiveness as a universal biopredictive tool for immediate-release carbamazepine products.
• The findings support the use of standardized dissolution media for predicting the in vivo performance of various oral immediate-release carbamazepine formulations.